Matches 1 - 50 out of 265 1 2 3 4 5 6 >


Match Document Document Title
US20140213510 USE OF PLEITROPHIN FOR PREVENTING AND TREATING PANCREATIC DISEASES AND/OR OBESITY AND/OR METABOLIC SYNDROME  
The present invention discloses the protein pleitrophin secreted by the developing pancreas, and polynucleotides, which identify and encode this protein. The invention also relates to the use of...
US20120129766 METHODS OF TREATING FGF21-ASSOCIATED DISORDERS  
The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods...
US20110144006 PROTEIN COMPOSITION  
The invention relates to a protein composition which upon ingestion by a healthy person with a normal fasting insulin level between 3.0-8.0 μU/L increases the insulin level to at most 20.0 μU/L....
US20140107025 OCULAR DRUG DELIVERY SYSTEM  
An ocular drug delivery system including a composition in which a formulation having an active agent such as rHGH and or an rHGH mimic, e.g., that increases insulin growth factor (IGF) or that...
US20140171361 METHODS FOR TREATING METABOLIC DISORDERS USING FGF  
The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidaemia, obesity, and fatty liver.
US20110002994 METHOD OF REGULATING THE TH17 PATHWAY AND ITS ASSOCIATED METABOLIC IMPACT  
It is disclosed a method of immunomodulating an immune response in a subject comprising administering to a subject a malleable protein matrix (MPM), from fermented whey, in an amount effective to...
US20120329710 Methods of Inducing Regulated Pancreatic Hormone Production in Non-Pancreatic Islet Tissues  
Disclosed are methods and pharmaceutical compositions for inducing pancreatic hormone production.
US20120046224 TREATMENT OF DIABETES AND METABOLIC SYNDROME  
Enterally administered calcitonin family members other than amylin, particularly calcitonin itself, are effective to treat Type I diabetes, Type II diabetes or metabolic syndrome, for mitigating...
US20130130976 METHODS OF TREATING AUTOIMMUNE DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS) AND NEURODEGENERATIVE DISEASES  
An insulin degrading enzyme (IDE) inhibitor for use in the treatment of a disease selected from the group consisting of an autoimmune disease of the central nervous system and a neurodegenerative...
US20130136738 Methods of Treating Glucose Metabolism Disorders  
Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided.
US20130130975 Methods of Treating Glucose Metabolism Disorders  
Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided.
US20130017994 Methods of Treating Glucose Metabolism Disorders  
Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided.
US20150005233 TREATMENT OF HYPOGLYCEMIA  
This invention provides compounds, compositions, and methods for treating hypogly.
US20140227265 METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING CLEC-2  
Methods of treating metabolic diseases and disorders using a Clec-2 extracellular domain are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, elevated glucose...
US20140051630 PERIOSTIN-INDUCED PANCREATIC REGENERATION  
A method for regenerating pancreatic tissue using recombinant periostin protein, a nucleic acid encoding said periostin and pharmaceutical compositions comprising said periostin are disclosed....
US20140315799 Compositions and Methods for Regulating Glucose Metabolism  
The present disclosure provides compositions for regulating glucose metabolism. The compositions provide for reduced levels of p75NTR and/or reduced binding of p75NTR to a GTPase such as Rab31 or...
US20130210713 COLLAGEN POWDER  
The invention is directed to a method for preparing a collagen powder and to collagen powder that can be used for the preparation of a satiety inducing food product. The collagen powder of the...
US20120028893 Adenovirus 36 E4 ORF 1 Gene and Protein and Their Uses  
Expression of the E4 orf 1 gene of Ad-36 alone has been discovered to be responsible for the increased insulin sensitivity observed in Ad-36 infected animals, including increased adipogenesis....
US20140309163 FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND TO MYOSTATIN  
The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat...
US20140107020 FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND TO MYOSTATIN  
The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat...
US20140105896 FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND TO MYOSTATIN  
The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat...
US20120046221 ALBUMIN FUSION PROTEINS  
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors...
US20130190230 COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DEFICITS  
A method of treating or preventing cognitive impairment deficits in subjects with age-associated cognitive decline or a dementing illness includes administering to the subject a therapeutically...
US20140336109 MODULATION OF GHRELIN LEVELS AND GHRELIN/UNACYLATED GHRELIN RATIO USING UNACYLATED GHRELIN  
A method and a composition for decreasing ghrelin levels and/or decreasing ghrelin/unacylated ghrelin ratio in a subject, the method comprising administering an effective amount of unacylated...
US20130157936 MODULATION OF GHRELIN LEVELS AND GHRELIN/UNACYLATED GHRELIN RATIO USING UNACYLATED GHRELIN  
A method and a composition for decreasing ghrelin levels and/or decreasing ghrelin/unacylated ghrelin ratio in a subject, the method comprising administering an effective amount of unacylated...
US20110166066 CATESTATIN (CST) AND ITS VARIANTS FOR TREATMENT OF CARDIOVASCULAR AND METABOLIC DISORDERS  
Circulating levels of catestatin (Cts: human chromogranin A352-372) decrease in the plasma of patients with essential hypertension. Genetic ablation of the chromogranin A (Chga) gene in mice...
US20140073563 FUSION PROTEINS FOR TREATING A METABOLIC SYNDROME  
The invention is directed to a fusion protein comprising at least one FGF-21 (fibroblast growth factor-21) compound and at least one GLP-1R (glucagon-like peptide-1 receptor) agonist as well as to...
US20120142582 Combination of Dopamine Agonists Plus First Phase Secretagogues for the Treatment of Metabolic Disorders  
The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central...
US20150024995 Combination Of Dopamine Agonists Plus First Phase Insulin Secretagogues For The Treatment Of Metabolic Disorders  
The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central...
US20150010508 Methods And Compositions Relating To Islet Cell Neogenesis  
The present invention provides methods and kits for treating diseases and conditions associated with impaired pancreatic function. The present invention further provides methods of stimulating...
US20150099697 METHOD FOR REVERSING RECENT-ONSET TYPE 1 DIABETES (T1D) BY ADMINISTERING SUBSTANCE P (sP)  
Described herein is a treatment comprising the following step: (a) injecting a therapeutically effective amount of a pharmaceutical composition into the celiac artery of an individual, wherein the...
US20120058938 NUTRITIONAL COMPOSITION INDUCING A POSTPRANDIAL ENDOCRINE RESPONSE  
The invention concerns the use of a nutritional composition for the treatment of disorders which are associated with malfunctioning in the uptake and use of food-derived energy in the human body....
US20140357556 Novel Target for Diagnosis and Treatment of Diabetes and Cardiovascular Diseases  
Diagnostic, prognostic, and treatment methods, compositions, and kits for enhancing insulin secretion and beta cell numbers and functions, and controlling glycemia associated with diabetes,...
US20140243259 GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOF  
The invention provides compositions and methods for ameliorating symptoms associated with hyperglycemia by administering a Zn-α2-glycoprotein or a functional fragment thereof, methods of...
US20070299010 CPG15 and CPG15-2 compounds and inhibitors as insulin receptor and insulin-like growth factor receptor agonists and antagonists  
Disclosed herein are CPG15 and CPG15-2 compounds and inhibitors that act as agonists and antagonists of the insulin receptor and insulin-like growth factor receptors, and the use of such...
US20070072810 Agent for treating diabetes  
An agent for treating diabetes with sulfonylurea secondary failure which comprises a dipeptidyl peptidase IV inhibitor. The agent of the present invention is an agent for treating diabetes with...
US20150126438 Novel ChREBP Isoforms and Methods Using the Same  
The invention provides diagnostic and prognostic methods and methods of evaluating treatment protocols for disorders such as obesity, diabetes, metabolic syndrome, cancer and vascular disease by...
US20130123172 Treatment of Type 2 Diabetes With FTY720  
The present disclosure provides therapeutic methods for prevention and treatment of type-2 diabetes comprising administering to the subject an effective amount of FTY720 or an analog.
US20050113287 Composition to enhance joint function and repair  
The present invention relates to a composition to enhance joint function, reduce inflammation and homocysteine levels, and repair cartilage. The present invention relates to a nutritional...
US20150182597 COMPOSITIONS COMPRISING HYALURONIC ACID AND DERMATAN SULPHATE FOR THE TREATMENT OF BEING OVERWEIGHT AND OBESITY  
The present invention relates to a composition comprising hyaluronic acid and dermatan sulphate for use in the treatment or prevention of overweight, obesity, insulin resistance, type 2 diabetes,...
US20140107026 BONE MORPHOGENETIC PROTEINS FOR THE TREATMENT OF INSULIN RESISTANCE  
The present disclosure relates to compositions and methods for treating insulin resistance and/or obesity in a cell and/or a subject
US20130109621 METHODS FOR INCREASING INSULIN SECRETION BY CO-STIMULATION OF CORTICOTROPIN-RELEASING FACTOR RECEPTORS  
Methods and compositions are provided for stimulating insulin production, increasing beta cell mass, or decreasing beta cell loss in a subject. For example, methods of the embodiments can comprise...
US20130085100 New Uses of Oxytocin-Like Molecules and Related Methods  
The present invention is directed to a derivative selected from oxytocin, an oxytocin derivative, and an oxytocin agonist useful for the treatment of a disorder selected from obesity and insulin...
US20060287251 Combination therapy for glycaemic control  
The present invention relates to method of treatment, in particular to a method for the treatment of diabetes mellitus, especially non-insulin dependent diabetes mellitus (NIDDM) or Type 2...
US20110319317 TREATMENT OF SIRTUIN 1 (SIRT1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SIRT1  
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sirtuin 1 (SIRT1), in particular, by targeting natural antisense polynucleotides of...
US20130195807 AGONISTS OF GROWTH HORMONE RELEASING HORMONE AS EFFECTORS FOR SURVIVAL AND PROLIFERATION OF PANCREATIC ISLETS  
Agonists of growth hormone releasing hormone promote islet graft growth and proliferation in patients. Methods of treating patients comprise the use of these agonists.
US20100318060 Injection Device With Rotatable Dose Setting  
An injection device comprising a housing and a dose setting mechanism including a dose setting element. Contrary to prior art injection devices, the dose setting element can only be set at a few...
US20150231204 PANCREATIC POLYPEPTIDE FAMILY MOTIFS, POLYPEPTIDES AND METHODS COMPRISING THE SAME  
The present invention provides novel Pancreatic Polypeptide Family (“PPF”) polypeptides and methods for their use.
US20150258208 PEGYLATED OXM VARIANTS  
A composition which includes oxyntomodulin and polyethylene glycol polymer (PEG polymer) linked via a reversible linker such as 9-fluorenylmethoxycarbonyl (Fmoc) or...
US20150148289 PEGYLATED OXM VARIANTS  
A composition which includes oxyntomodulin and polyethylene glycol polymer (PEG polymer) linked via a reversible linker such as 9-fluorenylmethoxycarbonyl (Fmoc) or...

Matches 1 - 50 out of 265 1 2 3 4 5 6 >